FDA approves Enhertu for HER2-positive early breast cancer
Statements (3)
- Neutral
Astra Zeneca has received EU approval for Enhertu as monotherapy for adjuvant treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted therapy.
- Neutral
Enhertu is approved in the EU as adjuvant treatment for HER2-positive early breast cancer patients with residual disease after neoadjuvant treatment
- Neutral
Enhertu is approved in the EU as an adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer